PHASE III RANDOMIZED STUDY OF ENZASTAURIN/R‐CHOP VS PLACEBO/R‐CHOP IN FRONTLINE HIGH RISK DIFFUSE LARGE B CELL LYMPHOMA PATIENTS WITH GENOMIC BIOMARKER DGM1 (ENGINE STUDY). (12th June 2019) - Zhu, J.; Song, Y.; Smith, S.D.; O'Connor, O.A.; Luo, W.; Shazer, R.L.; Zhang, L.; Han, I.; Jivani, M.A.; Liu, Y.; Nowakowski, G.S.